Tradestie Institutional Equity Comparison Engine

SGMO vs SRZN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SRZN Overall Edge

SRZN Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Momentum & Technical while SGMO counters with relative strength in Valuation, Options & Structure. Fundamentally, SGMO trades at 0.4x Forward P/E with -175.5% operating margin (+88.4% YoY revenue) versus SRZN at N/M Forward P/E and -485.4% operating margin (+408.6% YoY). In options structure, SGMO sits in UNCLASSIFIED (71st %ile IV; Dealer Gamma Walls on Pro) against SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner SGMO
SGMO 0.4x vs SRZN N/M Fwd P/E
Growth & Margin Winner SRZN
Op Margin -175.5% vs -485.4% ยท YoY +88.4% vs +408.6%
Momentum & Technical Winner SRZN
1Y -76.0% vs +171.8% ยท 52W Pos 9% vs 81%
Options & Structure Winner SGMO
UNCLASSIFIED (71st %ile IV) vs CONSOLIDATION (5th %ile IV)
SGMO NASDAQ
Sangamo Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.18
+31.56% 1D
Market Cap $55.9M
1M Return -40.82%
1Y Return -76.04%
Forward P/E 0.4x
Unified AI Score
52.0 / 100 HOLD
Tech 25.0 Fund 46.0 Flow 65.0 Mom 60.0
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$32.94
+4.21% 1D
Market Cap $603.7M
1M Return +40.53%
1Y Return +171.78%
Forward P/E N/M
Unified AI Score
32.8 / 100 SELL
Tech 50.0 Fund 32.0 Flow 64.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SGMO -76.04% SRZN +171.78% Spread: +225.06 pp (SRZN Lead)

Pillar 3 Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period SGMO Revenue SRZN Revenue SGMO Op. Margin SRZN Op. Margin Margin Edge
Q3 '25 $0M $0M -6119.3% -1107.3% SRZN
Q4 '25 $60M $0M -175.5% -2393.8% SGMO
Q1 '26 $10M $20M -2215.4% -209.1% SRZN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SGMO (4) vs SRZN (5)
Institutional Metric SGMO SRZN Criterion Row Winner
Market Capitalization Scale $55.9M $603.7M Larger Scale SRZN
Trailing P/E Ratio Valuation 0.4x N/M Lower Multiple SGMO
Forward P/E Ratio Valuation 0.4x N/M Lower Multiple SGMO
Revenue Growth (YoY) Growth +88.4% +408.6% Higher Growth SRZN
Operating Margin (TTM) Profitability -175.5% -485.4% Higher Margin SGMO
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -2891.8% -62.8% Higher ROE SRZN
52-Week Range Position Momentum 9% ($0โ€“$1) 81% ($12โ€“$38) Stronger Trend SRZN
Beta / 30D Volatility Risk Regime 1.49ฮฒ ยท 206% Vol 1.21ฮฒ ยท 62% Vol Lower Realized Risk SRZN
Unified Institutional Score Composite Signal 52.0 / 100 (HOLD) 32.8 / 100 (SELL) Higher Composite SGMO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SGMO vs SRZN Buy Guide
SGMO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 71st %ile
IV Regime Elevated (60thโ€“80th %ile)
Live SGMO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SRZN CONSOLIDATION
37d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SGMO nor SRZN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.